×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Prostate Cancer
Feature Video
Receiving a diagnosis of prostate cancer can be frightening and confusing. Understanding the details of your specific cancer and how they relate to your prognosis and treatment planning is an important first step toward shared decision-making between you and your physicians. In these CURE Connections programs you will learn the meaning of the PSA test, prostate cancer staging and grading, and how these factors are used to determine which treatment approach is right for you. Management of prostate cancer related symptoms, available treatments, and how to deal with side effects are also discussed. In addition, you will hear from patients and caregivers about their personal experiences with prostate cancer.
Beth Fand Incollingo
A clinical trial will test a radiation regimen designed to preserve sexual function in men being treated for prostate cancer.
Justin Birckbichler
It's more than the beard. It's about men's health.
Jessica Skarzynski
A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.
Katie Kosko
Although there is never the perfect time to have a risk-related discussion with a child, one clinical psychologist explains ways in which parents can approach the difficult topic.
Kristie L. Kahl
A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.
ARIELA KATZ
The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.
Jessica Skarzynski
Here are the top 5 CURE stories for September 2018.
Brielle Urciuoli
Prostate cancer is one of the most common cancers in males, with about one man in nine to be diagnosed during his lifetime, according to the American Cancer Society.
DEBU TRIPATHY, M.D.
Family history was one indicator that a man should undergo periodic screening, but it wasn’t until a couple of decades ago that scientists confirmed a link between inherited mutations of the BRCA gene and the development of prostate cancer.